Hawaii 2023 Regular Session

Hawaii Senate Bill SB1454

Introduced
1/25/23  
Refer
1/30/23  
Report Pass
2/17/23  
Refer
2/17/23  
Report Pass
3/2/23  
Engrossed
3/7/23  

Caption

Relating To Psilocybin.

Impact

If enacted, SB1454 would significantly influence state laws regarding the therapeutic use of psilocybin in Hawaii. By forming the working group, the state acknowledges the pressing mental health care shortage and is taking proactive steps to explore innovative treatment options. The findings from the working group's examinations will be compiled into a report with recommendations, potentially influencing future legislation related to psilocybin use in therapeutic contexts while addressing public health needs.

Summary

Senate Bill 1454 proposes the establishment of a Therapeutic Psilocybin Working Group within the Department of Health in Hawaii. The group is tasked with examining the medicinal and therapeutic effects of psilocybin or psilocybin-based products on various mental health issues, including post-traumatic stress disorder (PTSD), depression, anxiety, and psychological distress at the end of life. This legislation is informed by recent findings indicating that psilocybin has potential benefits in addressing such mental health conditions and seeks to replicate successful models observed in other states like Oregon and Colorado that have legalized its medicinal use.

Sentiment

The sentiment surrounding SB1454 appears largely supportive among proponents of mental health reform and innovative therapeutic solutions. Advocates argue that the mental health crisis calls for unconventional approaches, and psilocybin therapy could provide much-needed relief for those suffering from treatment-resistant conditions. However, there may also be concerns from skeptics regarding the safety and regulation of psilocybin use, indicating that the discourse is nuanced and varies across different stakeholder groups.

Contention

Notable points of contention could arise around the safety, regulation, and societal implications of using psilocybin in therapeutic contexts. Debate may center on whether the benefits of legalizing psilocybin as a treatment outweigh potential risks, such as misuse or insufficient oversight. Additionally, the timeline for the working group's findings, which is set to be reported before the 2025 regular session, indicates a temporary, exploratory phase which leaves room for public and expert feedback before any final legislation takes shape.

Companion Bills

HI HB1337

Same As Relating To Psilocybin.

Similar Bills

HI SB1454

Relating To Psilocybin.

HI HR206

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI SR153

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI HCR202

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI SCR133

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI HB1337

Relating To Psilocybin.

HI HB1337

Relating To Psilocybin.

HI SR88

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.